Patents Represented by Attorney Steven W. Collier
-
Patent number: 6869969Abstract: Isoxazole estrogen receptor agonist and antagonist compounds having unexpected and surprising activity in modulating estrogen receptor activity are described. In addition, methods and compositions for treating or preventing estrogen receptor-mediated disorders are disclosed. The compounds, methods, and compositions of the invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.Type: GrantFiled: November 13, 2003Date of Patent: March 22, 2005Assignee: Chiron CorporationInventors: Verena D. Huebner, Xiaodong Lin, Ian James, Liya Chen, Manoj Desai, Jennifer C. Moore, Beata Krywult, Thayalan Navaratnam, Rajinder Singh, Rob Trainor, Liang Wang
-
Patent number: 6783929Abstract: Provided are affinity support materials having intermediate binding affinity for biological samples. Among the materials provided by the present invention are hydrophilic solid supports composed of hydrophilic ligands coupled to hydrophilic matrixes which are compatible with biological samples, for example, a cell line, a biological fluid such as blood, or a tissue cell lysate. The ligands may include affinity property groups and hydrophilic groups pendent from a backbone, and be configured to at least partially resolve components of a biological sample. Affinity supports in accordance with the present invention may be used in a variety of techniques and apparatuses to achieve improved separations of complex biological samples and thereby enhance the results of biological sample component fractionations, enrichments, purifications, expression product determinations and comparisons, and other biological sample processing techniques.Type: GrantFiled: November 1, 2000Date of Patent: August 31, 2004Assignee: Chiron CorporationInventors: Ronald N. Zuckermann, Eric Beausoleil, Matthew Wachowicz, Srinivas Kothakota
-
Patent number: 6756359Abstract: Antimicrobial macrolide compounds are provided having formulas II: as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.Type: GrantFiled: July 3, 2002Date of Patent: June 29, 2004Assignee: Chiron CorporationInventors: Daniel Chu, Matthew Burger, Xiaodong Lin, Georgia Law Carroll, Jacob Plattner, Alice Rico
-
Patent number: 6727273Abstract: Estrogen receptor-modulating pyrazole compounds are described in addition to methods and compositions for treating or preventing estrogen receptor-mediated disorders. The compounds described have been found to have unexpected and surprising activity in modulating estrogen receptor activity. Thus, the compounds of the present invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.Type: GrantFiled: September 18, 2001Date of Patent: April 27, 2004Assignee: Chiron CorporationInventors: Verena D. Huebner, Xiaodong Lin, Ian James, Liya Chen, Manoj Desai, Beata Krywult, Rajinder Singh, Liang Wang
-
Patent number: 6716840Abstract: Compounds having the general structure I are provided: X and Y are independently selected from the group consisting of CH2, N, NR9, C═O, C═S, S═O, SO2, S, O, (CR6R7)n, C(═O)—(CR6R7)n, and C(═S)—(CR6R7)n, where n is 1, 2, or 3. W is selected from the group consisting of and L is selected from the group consisting of N, O, S, S═O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Z1, Z2, and Z3 are independently selected from the group consisting of substituted carbon and nitrogen. Compounds of formula I are agonists of the melanocortin-4 receptor (“MC-4r”) and therefore may have useful properties for controlling diseases related to MC-4r action in humans, such as obesity and type II diabetes.Type: GrantFiled: April 8, 2002Date of Patent: April 6, 2004Assignee: Chiron CorporationInventors: Daniel Chu, Rustum S. Boyce, David Duhl, Bryan H. Chang
-
Patent number: 6699844Abstract: Methods of treating cancer by administration of FMdC followed by administration of a platinate are disclosed.Type: GrantFiled: December 3, 2002Date of Patent: March 2, 2004Assignee: Chiron CorporationInventors: Richard E. Jones, Ning Y. Yu
-
Patent number: 6677445Abstract: Chimeric oligonucleotide of the formula 5′-W-X1-Y-X2-Z-3′, where W represents a 5′-O-alkyl nucleotide, each of X1 and X2 represents a block of seven to twelve phosphodiester-linked 2′-O-alkyl ribonucleotides, Y represents a block of five to twelve phosphorothioate-linked deoxyribonucleotides, and Z represents a blocking group effective to block nuclease activity at the 3′ end of the oligonucleotide, are described. These compounds exhibit high resistance to endo- and exonucleases, high sequence specificity, and the ability to activate RNAse H, as evidenced by efficient and long-lasting suppression of target mRNA.Type: GrantFiled: August 25, 2000Date of Patent: January 13, 2004Assignee: Chiron CorporationInventors: Michael A. Innis, Christoph J. Reinhard, Ronald N. Zuckermann
-
Patent number: 6608063Abstract: New bicyclic based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.Type: GrantFiled: December 14, 2000Date of Patent: August 19, 2003Assignee: Chiron CorporationInventors: John M. Nuss, Savithri Ramurthy
-
Patent number: 6605617Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.Type: GrantFiled: September 11, 2001Date of Patent: August 12, 2003Assignee: Chiron CorporationInventors: Paul A. Renhowe, Sabina Pecchi, Timothy D. Machajewski, Cynthia M. Shafer, Clarke Taylor, William R. McCrea, Jr., Christopher McBride, Elisa Jazan
-
Patent number: 6572881Abstract: In accordance with the present invention, there are provided lipid-conjugated polyamide compounds and related compositions and methods thereof. Lipid-conjugated polyamide compounds of the present invention are particularly useful as vehicles for delivering biologically active agents to a target site. In particular, the invention compounds are effective at facilitating the delivery of polynucleotides to cells. The present invention also provides a method for producing stable formulations of polynucleotides complexed with a delivery vehicle.Type: GrantFiled: July 21, 2000Date of Patent: June 3, 2003Assignee: Chiron CorporationInventors: Ronald N. Zuckermann, Chin-Yi Huang, John E. Murphy, Tetsuo Uno
-
Patent number: 6569450Abstract: In accordance with the present invention, there are provided lipid-conjugated polyamide compounds and related compositions and methods thereof. Lipid-conjugated polyamide compounds of the present invention are particularly useful as vehicles for delivering biologically active agents to a target site. In particular, the invention compounds are effective at facilitating the delivery of polynucleotides to cells. The present invention also provides a method for producing stable formulations of polynucleotides complexed with a delivery vehicle.Type: GrantFiled: July 21, 2000Date of Patent: May 27, 2003Assignee: Chiron CorporationInventors: Ronald N. Zuckermann, Chin-Yi Huang, John E. Murphy, Tetsuo Uno
-
Patent number: 6544962Abstract: Methods of treating cancer by administration of FMdC followed by administration of a platinate are disclosed.Type: GrantFiled: November 15, 2000Date of Patent: April 8, 2003Assignee: Matrix Pharmaceutical, Inc.Inventors: Richard E. Jones, Ning Y. Yu
-
Patent number: 6124346Abstract: A method of treating atherosclerosis, independent of lipid lowering, in mammals, including humans, in need of treatment by inhibiting progression of an atherogenic lesion or by stabilizing plaque. Such lesion progression inhibition or plaque stabilization is preferably achieved by directly inhibiting chemokine expression leading to excessive inflammatory cell recruitment by administering certain estrogen agonist/antagonists.Type: GrantFiled: September 28, 1999Date of Patent: September 26, 2000Assignee: Pfizer Inc.Inventor: Robert J. Aiello
-
Patent number: 6114395Abstract: A method of treating atherosclerosis, independent of lipid lowering, in mammals, including humans, in need of treatment by inhibiting progression of an atherogenic lesion or by stabilizing plaque. Such lesion progression inhibition or plaque stabilization is achieved by directly inhibiting chemokine expression leading to excessive inflammatory cell recruitment by administering a therapeutically effective amount of a compound of formula I.Type: GrantFiled: October 21, 1997Date of Patent: September 5, 2000Assignee: Pfizer Inc.Inventor: Robert J. Aiello
-
Patent number: 6069175Abstract: A method of treating atherosclerosis, independent of lipid lowering, in mammals, induding humans, in need of treatment by inhibiting progression of an atherogenic lesion or by stabilizing plaque. Such lesion progression inhibition or plaque stabilization is preferably achieved by directly inhibiting chemokine expression leading to excessive inflammatory cell recruitment by administering certain estrogen agonist/antagonists.Type: GrantFiled: October 21, 1997Date of Patent: May 30, 2000Assignee: Pfizer Inc.Inventor: Robert J. Aiello
-
Patent number: 6034102Abstract: A method of treating atherosclerosis, independent of lipid lowering, in mammals, including humans, in need of treatment by inhibiting progression of an atherogenic lesion or by stabilizing plaque. Such lesion progression inhibition or plaque stabilization is preferably achieved by directly inhibiting chemokine expression leading to excessive inflammatory cell recruitment by administering a therapeutically effective amount of a compound of formula I.Type: GrantFiled: October 21, 1997Date of Patent: March 7, 2000Assignee: Pfizer IncInventor: Robert J. Aiello